This could potentially exacerbate the metabolic effects of sarcopenic obesity given the decreased glucose uptake resulting from decreased muscle mass heightened by the inhibitory action of myostatin on insulin sensitivity. The gene discussed is MSTN; the disease is obesity disorder.